Dr. David Rimm, is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in Anatomic Pathology and Cytopathology. At Yale since 1994, Dr. Rimm is the Director of Yale Pathology Tissue Services and the Yale Tissue Microarray Facility. He is a member of the Executive Team in Pathology and serves as the Director of Translational Pathology. His lab group (15 researchers) focuses on quantitative pathology using the AQUA® technology invented in his lab with projects related to predicting response to therapy in breast cancer and predicting recurrence or metastasis in melanoma and lung cancer. He is currently supported by 9 grants from both public and private sources. He serves as a reviewer for the NIH and was a charter member of the Cancer Biomarkers Study Section. He is an editorial board member for 7 pathology journals and a member of the pathology committee for TransALLTO and TEACH (cooperative groups or therapeutic clinical trials). He is an author of over 275 peer-reviewed papers and 8 patents and was the scientific co-founder of HistoRx, a digital pathology company (sold to Genoptix in 2012) and Metamark Genetics, a prognostic determinant company.